Open an account

ImmuCell

ICCC · NASDAQ

$10.45−$0.06 (−0.57%)TodayMarket closed ·
Prev close $10.51

About ICCC

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 73 full-time employees. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

Employees
73
Headquarters
Portland, Maine
Listed
May 1, 1987
Sector
Health Care
Industry
Biotechnology
Website
immucell.com

ICCC key statistics

Market cap
94.91M
Price-earnings ratio
150.14
Dividend yield
—
Average volume
10.97K
Volume
4.20K
Open price
$10.49
High today
$10.51
Low today
$10.42
52 Week high
$12.10
52 Week low
$4.52

ImmuCell (ICCC) at a glance

As of Oct 20, 2026, ImmuCell (ICCC) shares are priced at $10.45, giving the company a market cap of 94.91M and a price-to-earnings ratio of 150.14.

Today the stock has traded between $10.42 and $10.51. The current price is 0.3% above the day's low and 0.5% below its high.

Volume so far is 4.20K shares, below the average of 10.97K shares a day.

Over the past year ImmuCell has ranged from $4.52 to $12.10, and now sits 78% of the way up that range.

ImmuCell met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.20 per share against an estimate of $0.00.

ICCC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 0.0% on average.

  1. Q3 FY24: reported -$0.09 per share against an estimate of $0.00
  2. Q4 FY24: reported $0.06 per share against an estimate of $0.00
  3. Q1 FY25: reported $0.16 per share against an estimate of $0.00
  4. Q2 FY25: reported $0.06 per share against an estimate of $0.00
  5. Q3 FY25: reported -$0.02 per share against an estimate of $0.00
  6. Q4 FY25: reported -$0.31 per share against an estimate of $0.00
  7. Q1 FY26: reported $0.21 per share against an estimate of $0.00
  8. Q2 FY26: reported $0.20 per share against an estimate of $0.00

ICCC news

  • ImmuCell Pauses Re-Tain Drug After FDA Setback, Shifts Focus to Expanding First Defense Business

  • Vandana Singh

    ImmuCell Puts Re-Tain On Pause After FDA Letter

  • Press releaseGlobe Newswire

    ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Avi Kapoor

    PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday

Similar companies

Companies in the same industry as ImmuCell

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.